Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

The investigators aim to investigate whether or not esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute ZRTN , and seek a safe, and effective treatment for refractory patients with ZRTN

Inclusion criteria

• Age >18 years;
• History of HZ within the last three months;
• Lesions located in the trigeminal nerve or its branches innervated regions；
• Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
• Planned to perform CT-guided PRF treatment of the Gasserian ganglion .

Exclusion criteria

• Obstructive sleep apnoea syndrome;
• Those who receive other invasive treatments, such as spinal cord stimulation;
• A history of systemic immune diseases, organ transplantation, or cancers;
• A history of severe cardiopulmonary, hepatic or renal dysfunction;
• A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
• Comorbid hyperthyroidism or phaeochromocytoma;
• Recent history of drug abuse;
• Having contraindications to esketamine;
• Communication difficulties.

Withdrawal criteria

• Lost to follow-up during the study;
• Not perform the planned operation;
• Receiving other treatment regimes during the study period;
• Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study;
• Voluntary withdrawal from the study.